![]() Premier Forms Pitocin Supply Partnership With Endo InternationalĮndo International plc Launches First Generic Version of Noxafil® (posaconazole) InjectionĮndo International plc Announces Approval of XCOPRI (Cenobam Tablets) in CanadaĮndo International plc Announces First Patient Enrolled in Registry of Dupuytren's ContractureĮndo International plc Launches Dexlansoprazole Capsules, Generic Version of DexilantĮndo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Financial Statements and Exhibits.ġ04 Cover Page Interactive Data File (embedded within the Inline XBRL document)īankrupt Endo says US government objections imperil $600 million in opioid settlements The information required by this Item 2.06 is included under Item 2.05 of thisĬurrent Report on Form 8-K and is incorporated herein by reference. Release included as Exhibit 99.1 to this Current Report on Form 8-K, which are The heading "Cautionary Note Regarding Forward-Looking Statements" in the press Various important factors, including the risks and uncertainties described under Actual results may differ materially as a result of The estimated savings, reductions, charges and costs noted above are subject toĪ number of assumptions. ![]() The Cleansing Materials are based solely on information available to the Materials is furnished herewith as Exhibit 99.2 to this Current Report on FormĨ-K. Occurrence of certain events as set forth in the NDAs. Pursuant to the NDAs, the Company has agreed to publiclyĭisclose certain information, including the Cleansing Materials, upon the ![]() In connection with the decision, Endo delivered materials pursuant toĬonfidentiality agreements (the "NDAs") entered into by the Company (the Ordinary course however, out of an abundance of caution, the Company will seekĮntry of an order from the United States Bankruptcy Court for the Southernĭistrict of New York approving this decision as a reasonable exercise of the The Company believes that it is authorized to make this decision in the To $20 million of cash costs related to employee separation costs and otherĬharges. Impairment charges of approximately $220 million to $230 million and $15 million These estimated restructuring charges primarily consist of non-cash asset Production and sales of QWO®, Endo expects to incur total pre-tax restructuringĬharges of approximately $235 million to $250 million in the fourth quarterĢ022. Workforce of approximately 90 full-time positions. This decision is expected to result in annualized pre-tax cash savings ofĪpproximately $50 million to $60 million and a reduction to Endo's global ![]() Of bruising following initial treatment as well as the potential for prolonged Histolyticum-aaes) in light of market concerns about the extent and variability Production and sale of Endo Aesthetics' QWO® (collagenase clostridium Indirect subsidiaries, "Endo" or the "Company") announced that it will cease the On December 6, 2022, Endo International plc (together with its direct and Costs Associated with Exit or Disposal Activities. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |